Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: Results of a population-based, propensity score-matched analysis

European Urology

Volumn 65, Issue 4, 2014, Pages 693-700

  Shao, Yu Hsuan Joni ^a   Kim, Sung ^b   Moore, Dirk F ^b,d   Shih, Weichung ^b,d   Lin, Yong ^b,d   Stein, Mark ^b,c   Kim, Isaac Yi ^b,c   Lu Yao, Grace L ^b,c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d RUTGERS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Neoplasm metastasis; Prostate cancer; Prostatectomy; Radiation therapy

Indexed keywords

NEOPLASM METASTASIS; PROSTATE CANCER; PROSTATECTOMY; RADIATION THERAPY;

AGED; AGED, 80 AND OVER; HUMANS; MALE; NEOPLASM METASTASIS; PROPENSITY SCORE; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 84894479221     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.05.023     Document Type: Article

References (30)

1. Y.H. Shao, P.C. Albertsen, W. Shih, C.B. Roberts, and G.L. Lu-Yao The impact of PSA testing frequency on prostate cancer incidence and treatment in older men Prostate Cancer Prostatic Dis 14 2011 332 339
2. Y.H. Shao, P.C. Albertsen, and C.B. Roberts et al. Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml Arch Intern Med 170 2010 1256 1261
3. M.H. Kawachi, R.R. Bahnson, and M. Barry et al. NCCN clinical practice guidelines in oncology: prostate cancer early detection J Natl Compr Canc Netw 8 2010 240 262
4. T.J. Wilt, R. MacDonald, I. Rutks, T.A. Shamliyan, B.C. Taylor, and R.L. Kane Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer Ann Intern Med 148 2008 435 448
5. A.S. Kibel, J.P. Ciezki, and E.A. Klein et al. Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era J Urol 187 2012 1259 1265
6. M.J. Zelefsky, J.A. Eastham, and A.M. Cronin et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix J Clin Oncol 28 2010 1508 1513
7. M.R. Cooperberg, A.J. Vickers, J.M. Broering, and P.R. Carroll Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer Cancer 116 2010 5226 5234
8. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
9. J.L. Warren, C.N. Klabunde, D. Schrag, P.B. Bach, and G.F. Riley Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population Med Care 40 2002 IV-3-18
10. Dolan M, Kim S, Shao Y-H, Lu-Yao G. Authentication of algorithm to detect metastases in men with prostate cancer using ICD-9 codes. Epidemiol Res Intl. In press. http://dx.doi.org/10.1155/2012/970406.
11. American Joint Committee on Cancer Manual for staging of cancer ed. 5 1997 JB Lippincott Philadelphia, PA
12. C.N. Klabunde, A.L. Potosky, J.M. Legler, and J.L. Warren Development of a comorbidity index using physician claims data J Clin Epidemiol 53 2000 1258 1267
13. D.V. Makarov, R. Desai, and J.B. Yu et al. Appropriate and inappropriate imaging rates for prostate cancer go hand in hand by region, as if set by thermostat Health Aff (Millwood) 31 2012 730 740
14. H. Putter, M. Fiocco, and R.B. Geskus Tutorial in biostatistics: competing risks and multi-state models Stat Med 26 2007 2389 2430
15. M. Schemper, and T.L. Smith A note on quantifying follow-up in studies of failure time Control Clin Trials 17 1996 343 346
16. R.B. D'Agostino Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 17 1998 2265 2281
17. D.P. Petrylak, C.M. Tangen, and M.H. Hussain et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
18. M.Y. Kim, T. Oskarsson, and S. Acharyya et al. Tumor self-seeding by circulating cancer cells Cell 139 2009 1315 1326
19. C.L. Chaffer, and R.A. Weinberg A perspective on cancer cell metastasis Science 331 2011 1559 1564
20. J.M. Crook, S. Malone, and G. Perry et al. Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival Cancer 115 2009 673 679
21. V. Tzelepi, E. Efstathiou, and S. Wen et al. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment J Clin Oncol 29 2011 2574 2581
22. R.C. Flanigan, S.E. Salmon, and B.A. Blumenstein et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655 1659
23. A.L. Alt, S.A. Boorjian, C.M. Lohse, B.A. Costello, B.C. Leibovich, and M.L. Blute Survival after complete surgical resection of multiple metastases from renal cell carcinoma Cancer 117 2011 2873 2882
24. S.A. Boorjian, R.H. Thompson, and M.K. Tollefson et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence Eur Urol 59 2011 893 899
25. A.J. Vickers, F.J. Bianco, and A.M. Serio et al. The surgical learning curve for prostate cancer control after radical prostatectomy J Natl Cancer Inst 99 2007 1171 1177
26. E.A. Klein, F.J. Bianco, and A.M. Serio et al. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories J Urol 179 2008 2212 2216 discussion 2216-7
27. L.M. Ellison, J.A. Heaney, and J.D. Birkmeyer The effect of hospital volume on mortality and resource use after radical prostatectomy J Urol 163 2000 867 869
28. Y.H. Shao, K. Demissie, and W. Shih et al. Contemporary risk profile of prostate cancer in the United States J Natl Cancer Inst 101 2009 1280 1283
29. J.A. Lane, F.C. Hamdy, R.M. Martin, E.L. Turner, D.E. Neal, and J.L. Donovan Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies Eur J Cancer 46 2010 3095 3101
30. T.J. Wilt, M.K. Brawer, and M.J. Barry et al. The Prostate Cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer Contemp Clin Trials 30 2009 81 87